» Articles » PMID: 39334841

Integrating Computational Design and Experimental Approaches for Next-Generation Biologics

Overview
Journal Biomolecules
Publisher MDPI
Date 2024 Sep 28
PMID 39334841
Authors
Affiliations
Soon will be listed here.
Abstract

Therapeutic protein engineering has revolutionized medicine by enabling the development of highly specific and potent treatments for a wide range of diseases. This review examines recent advances in computational and experimental approaches for engineering improved protein therapeutics. Key areas of focus include antibody engineering, enzyme replacement therapies, and cytokine-based drugs. Computational methods like structure-based design, machine learning integration, and protein language models have dramatically enhanced our ability to predict protein properties and guide engineering efforts. Experimental techniques such as directed evolution and rational design approaches continue to evolve, with high-throughput methods accelerating the discovery process. Applications of these methods have led to breakthroughs in affinity maturation, bispecific antibodies, enzyme stability enhancement, and the development of conditionally active cytokines. Emerging approaches like intracellular protein delivery, stimulus-responsive proteins, and de novo designed therapeutic proteins offer exciting new possibilities. However, challenges remain in predicting in vivo behavior, scalable manufacturing, immunogenicity mitigation, and targeted delivery. Addressing these challenges will require continued integration of computational and experimental methods, as well as a deeper understanding of protein behavior in complex physiological environments. As the field advances, we can anticipate increasingly sophisticated and effective protein therapeutics for treating human diseases.

Citing Articles

MicroRNAs in Plant Genetic Regulation of Drought Tolerance and Their Function in Enhancing Stress Adaptation.

Zhakypbek Y, Belkozhayev A, Kerimkulova A, Kossalbayev B, Murat T, Tursbekov S Plants (Basel). 2025; 14(3).

PMID: 39942972 PMC: 11820447. DOI: 10.3390/plants14030410.


Affinity Maturation for Antibody Engineering: The Critical Role of Residues on CDR Loops of Antibodies in Antigen Binding.

Yoshida M, Oda M Molecules. 2025; 30(3).

PMID: 39942636 PMC: 11819675. DOI: 10.3390/molecules30030532.

References
1.
Porello I, Cellesi F . Intracellular delivery of therapeutic proteins. New advancements and future directions. Front Bioeng Biotechnol. 2023; 11:1211798. PMC: 10247999. DOI: 10.3389/fbioe.2023.1211798. View

2.
Kim J, McFee M, Fang Q, Abdin O, Kim P . Computational and artificial intelligence-based methods for antibody development. Trends Pharmacol Sci. 2023; 44(3):175-189. DOI: 10.1016/j.tips.2022.12.005. View

3.
Esvelt K, Carlson J, Liu D . A system for the continuous directed evolution of biomolecules. Nature. 2011; 472(7344):499-503. PMC: 3084352. DOI: 10.1038/nature09929. View

4.
Huang P, Boyken S, Baker D . The coming of age of de novo protein design. Nature. 2016; 537(7620):320-7. DOI: 10.1038/nature19946. View

5.
Zahavi D, Weiner L . Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel). 2020; 9(3). PMC: 7551545. DOI: 10.3390/antib9030034. View